Barusiban suppresses preterm labor in monkeys
Author Information
Author(s): Torsten M Reinheimer, Jörg Strutwolf, Andrés López Bernal
Primary Institution: Ferring Pharmaceuticals A/S
Hypothesis
Barusiban, a selective oxytocin antagonist, is more effective than atosiban in suppressing oxytocin-induced preterm labor in non-human primates.
Conclusion
Barusiban effectively suppressed intrauterine pressure during daily oxytocin challenges, delayed labor, and prolonged pregnancy until term.
Supporting Evidence
- Barusiban was well tolerated and had a potency four times higher than atosiban.
- Both barusiban and atosiban demonstrated over 95% efficacy in suppressing contractions.
- Barusiban's duration of action was greater than 13 hours compared to atosiban's 1-3 hours.
Takeaway
This study shows that a new drug called barusiban can help pregnant monkeys stay pregnant longer by stopping early contractions.
Methodology
Pregnant cynomolgus monkeys were monitored for intrauterine pressure and treated with barusiban and atosiban to compare their effects on preterm labor.
Potential Biases
Potential bias due to the involvement of the sponsor, Ferring Pharmaceuticals, in the study.
Limitations
The study was conducted on a small sample size of monkeys, which may limit the generalizability of the results to humans.
Participant Demographics
Pregnant cynomolgus monkeys.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website